91 results
Page 3 of 5
6-K
EX-99.1
rvhz8gm
18 Jul 23
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
6:04am
6-K
EX-99.1
u53h47f2matsur
13 Jul 23
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
6:02am
6-K
EX-99.1
iemlk1si6ky3
10 Jul 23
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
8:43am
6-K
EX-99.1
151ekp
5 Jul 23
Report of Foreign Private Issuer
8:47pm
6-K
EX-99.1
mb08d wmi8f3f2
22 Jun 23
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
8:05pm
6-K
EX-99.1
egw1 fjivm
15 Jun 23
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
9:06pm
6-K
EX-99.1
0t7dhe1mjv
30 May 23
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
45bmcvyxyol pxn0ub
30 May 23
Entitlement Offer of Loyalty Options
8:00am
6-K
EX-99.1
hzgeyan 58h
18 May 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
qh7hp 1y2y
5 May 23
Report of Foreign Private Issuer
6:06am
6-K
EX-99.1
qp0j3 ehxq1l
2 May 23
Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
12:00am
6-K
EX-99.1
d78vh yiwxa
26 Apr 23
Incannex Healthcare March 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
9:40pm
6-K
EX-99.1
eczgsm7zc 8th
13 Apr 23
Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
9:23pm
6-K
EX-99.1
lxir2 h4qpzv34h6w
5 Dec 22
Report of Foreign Private Issuer
6:01am
6-K
EX-99.1
53t8etkuin9t8rn to76
28 Nov 22
Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases
8:19pm
6-K
EX-99.1
03q2yhups91v bx2i8kh
25 Nov 22
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O
6:08am
6-K
EX-99.1
ctu 3ttpxhanxmpimwb2
17 Nov 22
Report of Foreign Private Issuer
6:01am
20-F
wsc mkndhajd6zqyg
28 Oct 22
Annual report (foreign)
6:31am
6-K
EX-99.1
qjnvfebqv1fh9uyh
21 Oct 22
Report of Foreign Private Issuer
6:08am
6-K
EX-99.1
hdr5jn
11 Oct 22
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury
6:15am